Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Advanced Practice

Dronabinol Therapy: Central Nervous System Adverse Events in Adults With Primary Brain Tumors

Deborah “Hutch” Allen
CJON 2019, 23(1), 23-26 DOI: 10.1188/19.CJON.23-26

Dronabinol is an effective adjunct to antiemetic regimens during cancer treatment in several populations of patients with cancer. However, it has been used little in central nervous system (CNS) cancers because of concerns regarding potential CNS adverse events. This secondary analysis explored CNS adverse events reported by adults with primary brain tumors while receiving dronabinol during chemotherapy. The occurrence of CNS adverse events in this population was similar to that reported by patients in other oncology populations.

AT A GLANCE

  • CNS adverse events from dronabinol therapy are similar in adults with primary brain tumors and those with other cancer diagnoses.
  • CNS adverse events attributed to dronabinol therapy include somnolence, dizziness, cognitive disturbance, and aphasia.
  • Dronabinol therapy may be a useful adjunct to standard antiemetic therapy in adults with primary gliomas.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or